Original ArticlesTherapeutic Leukapheresis in Pediatric Leukemia: Utilization Trend and Early Outcomes in a US Nationwide CohortTakahashi, Takuto MD*; Turcotte, Lucie M. MD, MPH, MS*; Gordon, Peter M. MD, PhD*; Johnson, Andrew D. MD†; Rubin, Nathan MS‡; Spector, Logan G. PhD§ Author Information *Division of Pediatric Hematology/Oncology †Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology ‡Biostatistics Core, Masonic Cancer Center §Division of Epidemiology and Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, MN Research reported in this publication was supported by National Institute of Health grant P30 CA77598 utilizing the Biostatistics and Bioinformatics Core shared resource of the Masonic Cancer Center, University of Minnesota, and by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1-TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors declare no conflict of interest. Reprints: Takuto Takahashi, MD, Division of Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454 (e-mail: [email protected]). Journal of Pediatric Hematology/Oncology: March 2022 - Volume 44 - Issue 2 - p 47-53 doi: 10.1097/MPH.0000000000002140 Buy SDC Metrics Abstract Leukapheresis (LA) in pediatric leukemia is performed for leukostasis, a life-threatening emergency in the setting of extremely increased blast cell counts. The authors aimed to assess the epidemiology of pediatric leukemia who received LA. The authors reviewed US nationally representative admission records of patients less than 20 years of age in the Kids’ Inpatient Database for the years 2000, 2003, 2006, 2009, 2012, and 2016. Incidence of new leukemia cases who underwent LA were calculated for the years 2009, 2012, and 2016. Cox and logistic regression analyses were performed to ascertain the risk factors for adverse outcomes. There were 526 admissions for pediatric patients with acute lymphoblastic leukemia (ALL) (n=328), acute myeloid leukemia (AML) (n=124), or chronic myeloid leukemia (CML) (n=74) who underwent LA over the study period. The incidence of leukemia cases that required LA was lower in 2016 than in 2009 or 2012 (1.4%, 2.2%, and 2.7%, respectively; P=0.001). In-hospital mortality was higher in AML than ALL (hzard ratio, 3.2; 95% confidence interval, 1.1-9.1). None with CML died during admission. This first population-based study of LA in pediatric leukemia showed a decreased utilization of LA over recent years. The higher inpatient mortality in AML, as compared with ALL or CML, warrant further investigations. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.